ssalz’s Activity

Today

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 9:36 AM

ALNY in WSJ for the first time (I think)

Alnylam Pharmaceuticals Inc. would consider performance-based pricing if its experimental rare-disease drugs reach the market, CEO John Maraganore said in an interview. The company’s lead drug in development is a treatment for a rare disease called [more]

Yesterday

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 9:12 AM

Another new one

Tech Firms Seek Ways to Fend Off Activist Investors

Why LG’s Latest Android Watch Trails Apple’s

Are You Too Rigid?

A-HED
What’s Hot in the Art World? Algorithms

FIFA Officials Charged in Corruption [more]

Tue May 26

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 8:41 AM

More Science

– Company Expects to Present Initial Clinical Results in Early 2016 –

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 clinical trial with ALN-AS1, a [more]

Sun May 17

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 5:38 PM

The beat continues on

– Company Guides that it Plans to Initiate Phase 1/2 Trial in Late 2015 and Report Initial Clinical Results in Early 2016 –

– New Pre-Clinical Data with ALN-AAT Presented at Digestive Disease Week (DDW) Meeting, Showing Robust Knockdown of [more]

Thu May 14

NL

Boards Post

ssalz posted to the Berkshire Hathaway board. 10:26 AM

BRK and preventing train crashes

As USA Today noted 2 years ago, “Since 2005, the NTSB has investigated 15 train accidents in which 50 people were killed and 942 people were injured. In each case, the board concluded that positive train control would have prevented the [more]

Sun May 10

NL

Boards Post

ssalz replied to the ISIS Pharmaceuticals board. 9:55 PM

Re: STRONG EARNINGS/OUTLOOK

As long as the science is solid, the price will follow. Dr. Steve

Fri May 8

NL

Boards Post

ssalz replied to the Berkshire Hathaway board. 7:19 PM

Re: Berkshire meeting notes

Tell me about the three most important notes. Thanks, Dr. Steve

Mon May 4

NL

Boards Post

ssalz posted to the ISIS Pharmaceuticals board. 9:34 AM

More news

CARLSBAD, Calif., May 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of thrombosis. Under the [more]

Fri May 1

NL

Boards Post

ssalz posted to the ISIS Pharmaceuticals board. 12:21 PM

New milestone payment

The Wall Street Journal news department was not involved in the creation of this content.
PRESS RELEASE
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen
April 30, 2015 4:36 p.m. ET
CARLSBAD, Calif., April 30, 2015 [more]

Mon Apr 13

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 9:19 AM

A Primer on RNA interference from RGLS

About microRNAs

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not [more]

NL

Boards Post

ssalz posted to the Regulus Therapeutics, Inc. board. 9:18 AM

A primer of RNA interference

About microRNAs

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not [more]

Fri Apr 10

NL

Boards Post

ssalz posted to the Regulus Therapeutics, Inc. board. 8:49 AM

WSJ article includes RGLS

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, recently announced that the European Commission has granted orphan medicinal product designation [more]

Wed Apr 8

NL

Boards Post

ssalz posted to the Regulus Therapeutics, Inc. board. 8:33 AM

Another positive

LA JOLLA, Calif., April 7, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), [more]

Mon Mar 23

NL

Boards Post

ssalz replied to the ISIS Pharmaceuticals board. 9:00 PM

Re: Another promising event

Hopefully, both as an investor and a physician Dr. Steve

Fri Mar 6

NL

Boards Post

ssalz replied to the Berkshire Hathaway board. 9:41 PM

Re: BRK basis question

Thanks, Dr. Steve

NL

Boards Post

ssalz posted to the Berkshire Hathaway board. 7:49 PM

BRK basis question

1 b share say around 2001 worth 1800 per share. How to translate that into todays shares for a basis for selling. I forgot how many times the stock split.

Thanks, Dr. Steve

Tue Mar 3

NL

Boards Post

ssalz replied to the ISIS Pharmaceuticals board. 9:17 AM

Re: GSK MILESTONE

PS won't somebody come to the RGLS board. It is lonely there. I am the creator and only poster on the board for 1 whole year. Dr. Steve

NL

Boards Post

ssalz replied to the ISIS Pharmaceuticals board. 9:16 AM

Re: GSK MILESTONE

I think that it is "all about the science". If it holds up this will be a "rocket shoot" if it doesn't we chalk it up to experience and don't invest in early science. I think from everything I have read that the science will [more]

Sat Feb 28

NL

Boards Post

ssalz posted to the Berkshire Hathaway board. 8:00 PM

BRK price

How can I find the price of BRK stock in January 2002.

thx. Dr. Steve

Fri Feb 27

NL

Boards Post

ssalz posted to the ISIS Pharmaceuticals board. 9:59 AM

Year end wrap up pretty good

"2014 was another year of significant achievements for Isis with successes in every aspect of our business. We continued to advance our large pipeline of first-in-class or best-in-class drugs, including initiating Phase 3 programs for [more]

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 75240
Score 0.00
Score Change Today 0
Accuracy 0.00%
Active Picks 0
Total Picks 0
Best Pick ( 0)
Worst Pick ( 0)
Average Score per Pick 0.00
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to ssalz’s CAPS page

Boards Stats & Trivia

Big red star, 1000 posts Old School Fool
Board Posts 1031
Recs Received 2268
People who have rec'd these posts 585
Recs to Posts Ratio (last 30 days) N/A
Threads Started 351
Threads Started Percentage 34.04 %
Most Frequent Board Berkshire Hathaway
Very First Post Re: Amgen valuation (6/8/1999)
Percentage of Posts Rec'd 51.99 %
Show ssalz’s 10 Latest Posts